ArticleCPT: pharmacometrics & systems pharmacology2026
Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma.
Article in CPT: pharmacometrics & systems pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Subjects With Relapsed/Refractory Multiple Myeloma and Other Advanced Hematologic Malignancies Expressing BCMA
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
A simultaneous pharmacokinetic (PK)/pharmacodynamic (PD) analysis was conducted to characterize relationships between anti-B-cell maturation antigen (BCMA)-targeting antibody-drug conjugate, belantamab mafodotin, and longitudinal multiple myeloma (MM) disease markers (soluble BCMA [sBCMA], M-protein). Data from patients with relapsed/refractory MM receiving belantamab mafodotin monotherapy in the DREAMM-1 (NCT02064387), DREAMM-2 (NCT03525678), DREAMM-3 (NCT04162210), or DREAMM-5 (NCT04126200) trials were included. The dataset contained 510 patients with 15,860 PK and PD observations. Previous population PK and M-protein PD models were combined to create a new starting model. Overparameterization was reduced using sensitivity analyses to create a 2-compartment base model for belantamab mafodotin with a linear clearance component and target-mediated drug disposition assuming quasi-equilibrium between belantamab mafodotin and sBCMA binding. Free belantamab mafodotin affected M-protein elimination rate via a direct effect, and M-protein in turn scaled sBCMA synthesis rate. sBCMA was assumed to transfer into the central free sBCMA compartment through a reservoir compartment, allowing capture of observed differences in timescales. Stepwise covariate modeling led to the final model, which contained eight covariate effects (baseline sBCMA, albumin, body weight, and sex on belantamab mafodotin clearance; baseline body weight and sex on belantamab mafodotin central volume of distribution; extramedullary disease at screening and baseline sBCMA on M-protein death rate constant). Simulations of belantamab mafodotin doses/schedules showed concentrations of free sBCMA and M-protein decreased as free and total belantamab mafodotin increased with higher doses. The PKPD model captured the clearance of belantamab mafodotin and the highly dynamic interactions between belantamab mafodotin PK, M-protein, and sBCMA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.